Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients ...

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in ...

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and aggressive form of non-Hodgkin lymphoma, with a standard treatment approach typically involving R-CHOP. Despite overall favourable ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Palliative care for diffuse large B-cell lymphoma has significantly improved over the past several years, but disparities ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

NEW YORK, June 27, 2024 /PRNewswire/ -- The global diffuse large B-cell lymphoma (DLBCL) therapeutics market size is estimated to grow by USD 2.24 billion from 2024-2028, according to Technavio. The ...